within Pharmacolibrary.Drugs.ATC.L;

model L02AE02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.000139,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0165,
    k12             = 10.6,
    k21             = 10.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02AE02</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Leuprorelin (leuprolide acetate) is a synthetic gonadotropin-releasing hormone (GnRH) agonist, primarily used for the treatment of hormone-responsive cancers such as prostate cancer, endometriosis, uterine fibroids, and precocious puberty. It is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult males with advanced prostate cancer following a single subcutaneous 1 mg dose.</p><h4>References</h4><ol><li><p>Periti, P, et al., &amp; Mini, E (2002). Clinical pharmacokinetics of depot leuprorelin. <i>Clinical pharmacokinetics</i> 41(7) 485–504. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241070-00003&quot;>10.2165/00003088-200241070-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12083977/&quot;>https://pubmed.ncbi.nlm.nih.gov/12083977</a></p></li><li><p>Chrisp, P, &amp; Sorkin, EM (1991). Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. <i>Drugs &amp; aging</i> 1(6) 487–509. DOI:<a href=&quot;https://doi.org/10.2165/00002512-199101060-00008&quot;>10.2165/00002512-199101060-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1794035/&quot;>https://pubmed.ncbi.nlm.nih.gov/1794035</a></p></li><li><p>Seong, GS, et al., &amp; Jin, HE (2022). Determination of Leuprolide-Fatty Acid Conjugate in Rat Plasma Using LC-MS/MS and Its Pharmacokinetics after Subcutaneous Administration in Rats. <i>Molecules (Basel, Switzerland)</i> 27(24) –. DOI:<a href=&quot;https://doi.org/10.3390/molecules27248716&quot;>10.3390/molecules27248716</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36557850/&quot;>https://pubmed.ncbi.nlm.nih.gov/36557850</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02AE02;
